ACELRX PHARMACEUTICALS WKN: A1H64B ISIN: US00444T1007 Kürzel: R5X Forum: Aktien Thema: Hauptdiskussion

Übernahme durch acelrx aber Aktie fällt Merkwürdig

https://www.google.de/url?sa=t&source=web&rct=j&url=https://www.globallegalchronicle.com/acelrx-pharmaceuticals-32-5-million-acquisition-of-lowell-therapeutics/&ved=2ahUKEwiTrInejbv1AhUSR_EDHdd1CdYQxfQBKAB6BAgDEAI&usg=AOvVaw1_raPFCj8LfWXuibDEXA2s

Gute Wirksamkeit, reduzierter Opioideinsatz, kürzerer KH-Aufenthalt.

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-an-editorial-by-an-internationally-recognized-leader-in-opioid-sparing-surgery-highlighting-the-potential-advantages-of-the-sufentanil-sublingual-tablet-in-joint-replacement-surgery-301459074.html

https://www.streetinsider.com/dr/news.php?id=19361514&gfv=1

Mal sehen was die Zeit gibt Anders ist nichts zu machen als nur warten

Ist hier wirklich schwer zu beurteilen. Aber seit Anfang Dezember steht auch ein mögliches Delisting (mal wieder 🤪) im Raum: https://cbonds.com/news/1515143/

Gute news Totalverlust kann ich mir nicht vorstellen da sie einen zugelassenen Produkt haben. Höchstens wird sie aufgekauft. Oder sie müssen jetzt endlich ernten. Wann die Kassen klingeln ist auch eine Frage. Denke nicht vor 3.Q 2022

AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery https://finance-yahoo-com.cdn.ampproject.org/v/s/finance.yahoo.com/amphtml/news/acelrx-pharmaceuticals-announces-publication-clinical-133000197.html?amp_js_v=a6&amp_gsa=1&usqp=mq331AQKKAFQArABIIACAw%3D%3D#aoh=16395797382507&referrer=https%3A%2F%2Fwww.google.com&amp_tf=Von%20%251%24s&ampshare=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Facelrx-pharmaceuticals-announces-publication-clinical-133000197.html

Der kommt noch

👍👍👍

https://www.prnewswire.com/news-releases/acelrx-announces-14-million-registered-direct-common-stock-and-warrant-offering-301423906.html AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering

AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results https://finance.yahoo.com/news/acelrx-pharmaceuticals-acquire-lowell-therapeutics-110000897.html?guce_referrer=aHR0cHM6Ly9maW5hbmNlLXlhaG9vLWNvbS5jZG4uYW1wcHJvamVjdC5vcmcv&guce_referrer_sig=AQAAAN4f_cvH45LqbsPwo_CM9OSbSnDCrWfDZq17C1PF7uVQi6SxhIRiqk2WqPknYyMPlSGxYRMlzBOmT0beXT5WdDteVvHwQawM1AP0bjR5PyrcfaMBKG9Sy9kV-QpyeK6H_PIYbgFtPvHoOK7Fhxllpez2nz9Fat5BtGv8aKpZoE1A AcelRx to expand its pipeline with Niyad™, Lowell's investigational product that has received Breakthrough Designation status from the FDA Lowell provides AcelRx diversification into new therapeutic areas within medically supervised settings AcelRx had $48.7 million of cash and short-term investments as of September 30, 2021 DSUVIA® achieved 646 formulary approvals as of October 31, 2021, exceeding the year-end goal of 615 approvals AcelRx reports $1.9M total revenues in Q3 2021

Wer traut dieser Aktie noch bzw wer hat hier noch Hoffnung?

AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S. https://www.prnewswire.com/news-releases/acelrx-enters-into-licensing-agreement-for-dzuveo-in-europe-and-in-licensing-agreement-for-two-products-in-the-us-301333424.html AcelRx to receive up to approximately $55 million in combined up-front and sales-based milestone payments for DZUVEO licensing agreement AcelRx obtains the rights to file NDAs and commercialize two innovative pre-filled syringe product candidates for the U.S. ...

👍